Elsevier Acquires SciBite to Accelerate Solutions for Life Sciences and Corporate R&D Industries

SciBite, a semantic AI company headquartered in Cambridge, UK, to help customers make faster, more effective R&D decisions through advanced text and data intelligence solutions has been acquired by Elsevier, a global research publishing and information analytics provider, and part of RELX. SciBite’s solutions identify and extract scientific insights from structured and unstructured text and content, to identify key concepts such as drugs, proteins, companies, targets, and outcomes. The news was announced today (August 21, 2020). This semantically-enriched, machine-readable data, helps SciBite’s customers around the world make streamlined, more efficient decisions.

SciBite was founded in 2011 by Dr. Lee Harland, who currently serves as Chief Scientific Officer at the company, with a mission to help customers better understand the complexities of life sciences data. SciBite’s major products include: TERMite, an AI and ontology driven text analysis engine; DOCstore, which transforms search through semantic indexing; and CENtree, a next-generation collaborative ontology management platform; they are complemented by a suite of apps that support its core technology and allow customers to automate data-curation and manage terminology standards.

Dr. Harland said: “I am incredibly proud of everyone at SciBite; we believe that our continued investment in innovative technology enables our customers to address the huge challenges they face in creating, connecting and analyzing disparate content and data. Our track record in driving new insights and efficiencies within drug discovery and the wider life sciences is something we will continue to build upon in this next phase of our journey.”

Rob Greenwood, CEO and President, SciBite, said: “This is an exciting next step for our business. The combined offering of Elsevier’s high-quality content and data and the innovative technology from SciBite will deliver amazing value for any data led strategy across the scientific community. As part of the Elsevier organization, SciBite will have the ability to deliver enterprise technology, and new advances in scientific insight and discovery across its broad reaching global customer base.”

Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. To support this, Elsevier’s Life Sciences Solutions division is transforming from a provider of reference solutions into a creator of data and information analytics capable of supporting multiple scientific domain-specific use cases, ranging from search and discovery through to machine learning and AI.

SciBite’s proven and award-winning solutions will enable Elsevier to develop its Life Sciences Solutions services, such as: Reaxys, which powers chemistry research and development; Embase, the world’s most comprehensive international database of biomedical information; and Entellect, its FAIR data compliant platform that integrates, stores, and enriches client data with Elsevier and third-party content into a common analytical environment.

Cameron Ross, Managing Director Life Sciences Solutions, Elsevier, said: “The life sciences and corporate R&D communities face complex challenges, with an ever-expanding sea of data and content to extract knowledge from. We aim to combine Elsevier’s expertise and content from existing products, with SciBite’s impressive capabilities and suite of ontology-led products, to support more customers around the world make data led decisions in the drug development process.”

Stuart Whayman, Chief Commercial Officer, Elsevier, said: “Elsevier and SciBite have an aligned vision to better understand the complexities of the life sciences to better serve our customers, a vision which we believe will create exciting opportunities in the future. I am very pleased to welcome the SciBite team to Elsevier and look forward to working with them in the future.”

SourceElsevier

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”